Lead Sponsor

Actelion

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

No

•1. Signed informed consent prior to initiation of any study mandated procedure
•2. Male or female ≥ 40 and ≤ 75 years of age
•3. Women of childbearing potential1 must use a reliable method of contraception
•4. Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on pulmonary function tests
•5. Current or past smokers of ≥ 10 pack years
•6. Ability to perform exercise testing without supplemental oxygen (in the best opinion of the investigator)
•7. Confirmed pulmonary hypertension by right heart catheterization (RHC)

•1. Other causes of pulmonary hypertension than COPD
•2. BMI \> 35 kg/m2
•3. Conditions considered as contraindications for cardiopulmonary exercise testing (CPET) and/or inability to pedal on a cycle ergometer
•4. Pregnant or nursing
•5. Currently (within 30 days prior to RHC) taking specific pulmonary arterial hypertension (PAH) therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil, epoprostenol, treprostinil, iloprost, beraprost)
•6. Participation in any other clinical trial, except observational, or receipt of an investigational product within 30 days prior to RHC visit
•7. Known concomitant life-threatening disease with a life expectancy \< 12 months
•8. Known hypersensitivity to iloprost or any of the excipients of the drug formulations

Related studies

NCT07190209 · Chronic Obstructive Pulmonary Disease

NCT05746039 · Obesity, Interstitial Lung Disease, and more

NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07073950 · Chronic Obstructive Pulmonary Disease, Hyperinflation

NCT07509606 · Chronic Obstructive Pulmonary Disease (COPD), Whole Body Vibration

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)